Cornea alkali burn is caused by exposure of the eye to alkaline substances. The pH, degree of contact, and duration of exposure determine the severity of the injury.[@bib1]^,^[@bib2] The strong alkali causes tissue saponification. The damaged tissues then undergo liquefactive necrosis, causing an inflammatory response that leads to the release of proteolytic enzymes that further damage the tissues.[@bib2]^--^[@bib5]

Research indicates that increased synthesis of TGF-β1 following corneal alkali injury helps the healing process. It promotes the migration of keratocytes and epithelial cells to the site of the injury, causes chemotaxis of monocytes and macrophages, and induces myofibroblasts transdifferentiation.[@bib6]^--^[@bib8] However, its overexpression induces the expression of vascular endothelial growth factor (VEGF) and monocyte/macrophage chemotactic protein-1 (MCP-1),[@bib9]^,^[@bib10] which cause local neovascularization and inflammation, respectively,[@bib11]^--^[@bib14] resulting in fibrosis. Preventing the overexpression of TGF-β1 and its downstream signaling effects is thus critical in preventing fibrosis.

5′-Adenosine monophosphate-activated protein kinase (AMPK) is a cellular energy sensor that is activated by an increased intracellular AMP/adenosine triphosphate (ATP) ratio.[@bib15] It is also activated by AMP/ATP ratio-independent pathways, such as the Ca^2+^/calmodulin-dependent protein kinase.[@bib16] In addition to these physiological conditions, AMPK is activated by pharmacological agents such as 5-amino-4-imidazole carboxamide riboside-1-β-[d]{.smallcaps}-ribofuranoside (AICAR), which is an adenosine analog. AICAR is taken up into the cells by adenosine transporters on the cell membrane and subsequently phosphorylated by adenosine kinase to 5-amino-1-β-[d]{.smallcaps}-ribofuranosylimidazole-4-carboxamide-5′-monophosphate (ZMP), which mimics AMP and thus stimulates AMPK activation.[@bib17]^,^[@bib18] AMPK activation has several effects, including modulation of protein synthesis, glucose and lipid metabolism, regulation of cytokine production and inflammation, and cellular proliferation and apoptosis.[@bib19]^--^[@bib22] In addition, the activation of AMPK by AICAR has been shown to exhibit antifibrotic effects in several cell types,[@bib23]^--^[@bib27] making it a potential therapeutic agent in countering fibrosis. Its role in corneal fibrosis, however, has yet to be investigated. This study focused on the antifibrotic effect of AICAR in the cornea and the molecular mechanisms involved.

Methods {#sec2}
=======

Ethical Statement {#sec2-1}
-----------------

The animal study was approved by the Yonsei University Wonju College of Medicine (YWC-170410-1). All of the experiments were carried out in accordance with the guidelines issued by the Animal Care and Ethics Committee on Research at Yonsei University Wonju College of Medicine, in accordance with the tenets of the Helsinki Declaration, and conducted with adherence to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Isolation and Culture of Primary Human Cornea Fibroblasts {#sec2-2}
---------------------------------------------------------

Primary human corneal fibroblasts were obtained from the corneal limbus after removal of the central corneal buttons for corneal transplantation. Briefly, the other cornea layers, including the epithelium and endothelium, were removed with Dispase II digestion (Sigma-Aldrich, St. Louis, MO, USA) and scraping under a microscope. The stromal layer was then washed three times with sterile PBS (Welgene, Gyeongsan, Korea), and the tissue was digested with 2 mg/mL collagenase and 0.5 mg/mL hyaluronidase (Sigma-Aldrich) prepared in Dulbecco\'s Modified Eagle Medium/Nutrient Mixture F12 (DMEM/F12) (Thermo Fisher Scientific, Waltham, MA, USA) medium for 3 hours with shaking at 37°C. After digestion, the isolated cells were collected by centrifugation (12000×g for 5 minutes), resuspended in DMEM/F12 supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic/antimycotic (Thermo Fisher Scientific), and incubated at 37°C with 5% CO~2~ in a humidified incubator.[@bib28] The cells were passaged with 0.25% trypsin and cultured in DMEM supplemented with 5% FBS and 1% antibiotic/antimycotic. The culture medium was changed every 2 to 3 days until passaging at 80% confluency. The cells at passages 3 to 10 were stored at --80°C for subsequent use.

In Vitro Analyses {#sec2-3}
-----------------

In vitro analyses were performed by directly stimulating primary corneal fibroblasts with TGF-β1 to induce fibrosis. The fibroblasts were seeded into culture plates and allowed to attach. The cells were pretreated with 0.5-mM and 1-mM AICAR (Abcam, Cambridge, UK) dissolved in dimethyl sulfoxide for 2 to 3 hours followed by 5 ng/mL TGF-β1 (PeproTech, Seoul, Korea) and then incubated. To determine if the observed effects were AMP-activated protein kinase (AMPK) dependent, the cells were pretreated for 2 hours with 2.5-µM and 5-µM Compound C (Merck, Darmstadt, Germany), an AMPK antagonist, followed by 1-mM AICAR for 2 hours and then 5-ng/mL TGF-β1, and then incubated. The incubation periods were 8 hours for the detection of signaling proteins and 48 hours for the detection of ECM proteins.

Western Blotting {#sec2-4}
----------------

Total protein was extracted using radioimmunoprecipitation assay buffer (Thermo Fisher Scientific) with protease and phosphatase inhibitors (Sigma-Aldrich). Equal amounts of the proteins were resolved on 10% SDS-PAGE and transferred onto polyvinylidene fluoride membrane (MilliporeSigma, Burlington, MA, USA). The protein blots were analyzed with Pierce enhanced chemiluminescence western blotting substrate (Thermo Fisher Scientific). Images were captured using a UVP BioSpectrum 600 imaging system (Ultra-Violet Products Ltd., Cambridge, UK). The relative expressions of target proteins were evaluated by densitometry using ImageJ software (<http://imagej.nih.gov/ij/index.html>). Antibody information is provided in [Supplementary Table S1](#iovs-61-6-43_s001){ref-type="supplementary-material"}.

RNA Isolation and Quantitative Real-Time PCR {#sec2-5}
--------------------------------------------

For quantitative real-time PCR analysis, the fibroblasts were seeded and treated with AICAR and TGF-β1 as already described. After 24 hours of incubation, the cells were harvested and total RNA extracted using an RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer\'s protocol. The quality and quantity of the RNA extracts were assessed by spectrophotometry. The RNA was reverse-transcribed to cDNA with LaboPass cDNA synthesis kit (Cosmo Genetech, Seoul, Korea) according to the manufacturer\'s protocol. Quantitative PCR was performed using primer pairs of target genes listed in [Supplementary Table S2](#iovs-61-6-43_s002){ref-type="supplementary-material"}. The reaction was performed in a 10-µL reaction volume with the Applied Biosystems SYBR Green PCR Master Mix (Thermo Fisher Scientific).

Collagen Gel Matrix Contraction Assay {#sec2-6}
-------------------------------------

Cells were resuspended in serum-free DMEM at a concentration of 1.5 × 10^5^ cells/mL; 400 μL of the cell suspension was mixed with 200 μL of type I collagen from a Gibco rat tail tendon solution (Thermo Fisher Scientific), and 5 μL of 1-N NaOH was added to neutralize the mixture. The gel solutions were added to 24-well plates (600 µL per well) and incubated at 37°C for 30 minutes to polymerize. Next, 600 µL of DMEM mixed with vehicle, 5-ng/mL TGF-β1, or 5-ng/mL TGF-β1 plus 1-mM AICAR, constituting the three different treatment regiments, were added to the gels. The gels were dissociated from the wells and incubated at 37°C and 5% CO~2~ in a humidified incubator. Contraction images of gels were captured at different time points using a digital camera at a fixed distance. The degree of contraction was quantified by measuring the surface area using Image J software. The experiment was done in triplicate for each treatment group.

Animal Work {#sec2-7}
-----------

Healthy 8-week-old male BALB/C mice used in this study were kept under standard animal room conditions (temperature, 24°C ± 1°C; humidity, 50% ± 5%) for 1 week to acclimatize. After acclimatization, alkali burns were inflicted on the right eye of the mice, using the following protocol: First, the mice were randomly divided into four groups of six. They were then anesthetized with isoflurane followed by placement of 2-mm-diameter filter paper soaked with 2 μL of 0.1-N NaOH solution on the central cornea for 30 seconds to cause a grade I to II burn.[@bib29] The eyes were thoroughly washed with sterilized physiological saline. The mice were housed in plastic cages and fed a normal diet, with a 12-hour/12-hour light/dark cycle. Topical application of drugs was done 4× daily. Group 1 mice served as positive controls and were not treated with the test drugs. Group 2 mice were treated with 1-mM AICAR. Group 3 mice were treated with steroid (0.1% flumetholone; Santen Pharmaceutical, Osaka, Japan). Group 4 mice were treated with 1-mM AICAR and steroid. In order to prevent bacterial infection, all of the injured eyes were treated with a topical antibiotic (0.5% levofloxacin; Santen). The uninjured left eye corneas were used as negative controls. The mice were euthanized after 21 days by cervical dislocation after anesthesia with isoflurane. The central cornea, over a 3.0-mm^2^ area, was scanned with the anterior segment 5 line raster method using CIRRUS HD-OCT (Carl Zeiss Meditec, Jena, Germany). The corneas were harvested and protein extracted for western blotting*.* Briefly, the tissues were excised and homogenized using TissueLyser II (QIAGEN) in a suitable lysis buffer---125-mM Tris-HCl, pH 7.0; 0.1% Triton X-100 (Sigma-Aldrich); 0.1% Tween 20 (Sigma-Aldrich); 100 mM NaCl; and 0.1% SDS---for optimal protein extraction as shown in a previous study.[@bib30] The homogenate was centrifuged at 10,000×*g* for 5 minutes at 4°C, and the supernatant with the extracted protein was collected and stored at −20°C. Harvested cornea tissues were also fixed in 10% phosphate-buffered formalin for histopathological analysis.

Immunohistochemistry {#sec2-8}
--------------------

Paraffin sections of the corneal tissues were deparaffinized, rehydrated, and analyzed by immunohistochemistry using monoclonal antibodies against α-smooth muscle actin (α-SMA) (1:500) and fibronectin (1∶500) incubated overnight at 4°C. Biotinylated secondary antibody and streptavidin--biotin--peroxidase (1∶200, incubated for 1 hour at 37°C) were used to detect the target proteins. The sections were counterstained with hematoxylin, dehydrated, and mounted.

Statistical Analysis {#sec2-9}
--------------------

The data were analyzed using Prism 5.0 software (GraphPad, San Diego, CA, USA). Statistical comparisons were done using ANOVA, and post-test analysis was performed using Tukey\'s multiple comparison as appropriate. Statistical significance was defined as *P* \< 0.05 in all cases.

Results {#sec3}
=======

AICAR Suppressed TGF-β1 and Extracellular Matrix Protein Accumulation in Corneal Fibroblasts Following Alkali Injury {#sec3-1}
--------------------------------------------------------------------------------------------------------------------

To examine the possible mechanisms that may be involved in the antifibrotic effect of AICAR, we looked at TGF-β1 protein synthesis in response to alkali burn. Corneal tissues of mouse models of alkali burns, treated with or without AICAR, and uninjured control cornea tissues were analyzed by western blotting. Results showed that alkali injury caused a significant increase in TGF-β1 protein synthesis, which caused a corresponding significant increase in myofibroblast differentiation. Treatment with AICAR, however, resulted in a significant decrease in the TGF-β1 protein synthesis (*P* = 0.0091) ([Fig. 1](#fig1){ref-type="fig"}). The decreased TGF-β1 protein synthesis was seen to correspond also to a decreased myofibroblast differentiation and extracellular matrix (ECM) protein synthesis in the group treated with AICAR compared with the untreated group (α-SMA, *P* = 0.0133; fibronectin, *P* = 0.0118) ([Fig. 1](#fig1){ref-type="fig"}). Immunohistochemistry images of the mice corneal tissues also showed a marked decrease in the expression of fibronectin and α-SMA in the groups treated with AICAR compared with the untreated groups ([Fig. 2](#fig2){ref-type="fig"}).

![Effect of AICAR on alkali burn-induced ECM protein and TGF-β1 expression. Representative western blots and their quantitative analysis showing alkali burn-induced expression of TGF-β1, fibronectin, and α-SMA. AICAR treatment (1 mM) resulted in decreased expression of these proteins as shown. ^\#^*P* \< 0.05 compared to vehicle-treated control cells; ^\*^*P* \< 0.05 compared to cells treated only with NaOH.](iovs-61-6-43-f001){#fig1}

![Immunohistochemistry images of mice cornea. Histopathological analysis of mice corneal tissues showing a marked decrease in the expression of fibronectin and α-SMA in the groups treated with AICAR compared with the untreated groups 3 weeks after alkali injury. Magnification is 200×.](iovs-61-6-43-f002){#fig2}

OCT images of the mice cornea showed irregular epithelium and increased stroma thickness with high hyperreflectivity indicating excessive neovascularization and fibrosis in the untreated group. Conversely, mice treated with AICAR showed a more homogeneous, less hyperreflective, and more regular corneal thickness, indicating reduced ECM protein synthesis and confirming the western blotting results ([Supplementary Figure Fig. S1](#iovs-61-6-43_s003){ref-type="supplementary-material"}).

Induction of fibrosis in vitro by directly treating cells with TGF-β1 also led to a marked increase in the expression of α-SMA, fibronectin, and the fibronectin EDA isoform (EDA-FN) compared with vehicle-treated control cells. AICAR pretreatment, however, significantly suppressed the expression of these proteins (*P* = 0.0024 for α-SMA and *P* \< 0.0001 for fibronectin and EDA-FN) ([Fig. 3](#fig3){ref-type="fig"}A). The western blots were confirmed by real-time PCR results, which also showed a significantly decreased relative mRNA transcription of these proteins, as well as collagen 1 (*P* = 0.0025 for α-SMA; *P* \< 0.0001 for fibronectin; *P* = 0.0368 for EDA-FN; *P* = 0.0014 for collagen 1) ([Fig. 3](#fig3){ref-type="fig"}B).

![Effect of AICAR on TGF-β1-induced ECM protein expression and myofibroblast differentiation. (**A**) Representative western blots and their quantitative analysis showing a significant antifibrotic effect of AICAR on TGF-β1-induced expression of α-SMA, EDA-FN, and fibronectin. (**B**) Analysis of mRNA transcript levels also shows a significant antifibrotic effect of AICAR on TGF-β1-induced transcription of α-SMA, fibronectin, collagen, and EDA-FN. ^\#\#^*P* \< 0.01 and ^\#\#\#^*P* \< 0.001 compared to vehicle-treated control cells; ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, and ^\*\*\*^*P* \< 0.001 compared to cells treated only with TGF-β1.](iovs-61-6-43-f003){#fig3}

AICAR Suppressed Fibroblast Contraction {#sec3-2}
---------------------------------------

Collagen contractility is a characteristic of activated fibroblasts. To confirm the effect of AICAR on activated fibroblasts and subsequently on myofibroblast differentiation, the collagen gel matrix contraction assay was used. Our results showed AICAR suppressed fibroblast activation by TGF-β1. The cells treated with AICAR showed less contraction of the gel area compared with those treated with only TGF-β1 ([Fig. 4](#fig4){ref-type="fig"}). Although a slight difference in cell contraction was observed between the vehicle-treated controls and AICAR treated groups, it was not significant.

![Collagen gel matrix contraction images. (**A**) Representative gel images and (**B**) the quantitative analysis of percentage gel area showed no significant difference in gel contraction between the vehicle-treated control cells and cells treated with TGF-β1 plus AICAR (1 mM) throughout the test period. However, the vehicle-treated control cells and cells treated only with TGF-β1 showed significant differences in gel contraction from test day 3. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, and ^\*\*\*^*P* \< 0.001 compared to vehicle-treated control cells.](iovs-61-6-43-f004){#fig4}

Anti-Fibrotic Effect of AICAR Is Dependent on AMPK Signaling {#sec3-3}
------------------------------------------------------------

To investigate the molecular mechanism of AICAR in the inhibition of corneal fibrosis, we pretreated the primary human corneal fibroblasts with the AMPK-specific signaling inhibitor Compound C. First, we confirmed the activation of the AMPK signaling by AICAR. The result showed a significant increase in phosphorylated AMPK protein synthesis in the primary human corneal fibroblasts with TGF-β1 treatment (*P* = 0.0007). As shown in our results, Compound C treatment significantly blocked the antifibrotic effects of AICAR, depicted by the significantly high expression of α-SMA (*P* = 0.0003) and fibronectin (*P* = 0.0041) subsequent to the significantly suppressed AMPK signaling after TGF-β1 stimulation (*P* \< 0.0001) ([Fig. 5](#fig5){ref-type="fig"}).

![Effect of inhibition of AMPK signaling on the antifibrotic effect of AICAR. (**A**) Representative western blots and their quantitative analysis showed a significant increase in AMPK activation after AICAR treatment. (**B**) Blots also show that AICAR treatment caused a significant decrease in the TGF-β1-induced expression of α-SMA and fibronectin, which was countered by Compound C treatment subsequent to a significant decrease in AMPK level. ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 compared to vehicle-treated control cells; ^\*\*^*P* \< 0.01 and ^\*\*\*^*P* \< 0.001 compared to cells treated only with TGF-β1.](iovs-61-6-43-f005){#fig5}

AICAR Suppressed Mammalian Target of Rapamycin Signaling {#sec3-4}
--------------------------------------------------------

AMPK activation has been known to inhibit mammalian target of rapamycin (mTOR) signaling; thus, we studied the effects of AICAR on mTOR signaling in the corneal fibroblasts. The results indicated that AMPK activation by AICAR resulted in a correspondent significant decrease in phosphorylated mTOR (*P* = 0.0004) and phosphorylated p70S6K (*P* = 0.0001) expression, indicating mTOR signaling inhibition ([Fig. 6](#fig6){ref-type="fig"}).

![Effect of AICAR on mTOR signaling. Representative western blots of phosphorylated mTOR and phosphorylated p70S6K and their quantitative analysis showing the suppressive effect of AICAR on these signaling pathways after TGF-β1-induced signaling. ^\#\#\#^*P* \< 0.001 compared to vehicle-treated control cells; ^\*\*^*P* \< 0.01 and ^\*\*\*^*P* \< 0.001 compared to cells treated only with TGF-β1.](iovs-61-6-43-f006){#fig6}

Discussion {#sec4}
==========

Chemical injuries to the eye represent about 11.5% to 22.1% of all ocular traumas, with alkali substances being responsible for about 60% of these injuries.[@bib31]^--^[@bib33] These injuries present with very severe consequences due to the lipophilic nature of alkali, which enables them to penetrate the eye more deeply through saponification of membrane lipids. Severe damage to the corneal and conjunctival epithelium may cause damage to the pluripotent limbal stem cells, thus destroying their ability to regenerate and maintain the cornea. Alkali substances also denature the collagen matrix of the cornea, further penetrating into the corneal stroma.[@bib2] The transparent nature of the cornea is important for its proper functioning; therefore, a normal healing response to a corneal injury involves events that work to retain its normal stromal structure and function. An abnormal healing response, however, leads to the loss of corneal transparency due to myofibroblast differentiation of the stromal keratocytes and fibrosis.[@bib34]^,^[@bib35] The opaque nature of these myofibroblasts is partly due to a reduced production of corneal crystallin and increased production of disorganized ECM proteins.[@bib36]^,^[@bib37] Our results confirm these previous findings, as they showed increased ECM protein synthesis and myofibroblast differentiation after alkali injury; however, treatment with AICAR suppressed these fibrotic responses significantly ([Figures 1](#fig1){ref-type="fig"} to [4](#fig4){ref-type="fig"}). The OCT images obtained also showed less epithelial damage and reduced inflammation and corneal opacity ([Supplementary Fig. S1](#iovs-61-6-43_s003){ref-type="supplementary-material"}) in the group treated with AICAR. We also examined the effectiveness of AICAR and 0.1% flumetholone as a combined therapy, as this steroid is used for suppressing inflammation and minimization scarring. Our OCT images showed much improvement in epithelial healing, significantly reduced corneal inflammation and opacity, and an overall improved appearance of the cornea compared to the groups treated with only AICAR or flumetholone ([Supplementary Fig. S1](#iovs-61-6-43_s003){ref-type="supplementary-material"}). Further research into such combination therapies presents a great prospect to lowering dosage and application period of these steroids, thus minimizing their adverse effects, such as raised intraocular pressure, cataract, and suppression of immune response.[@bib38]

The increased synthesis of TGF-β1 after corneal injury has been implicated in the development of ocular fibrosis in several studies.[@bib39]^--^[@bib45] TGF-β1 and its receptors are expressed in the epithelium and stromal layers of the cornea. It is known to have inhibitory effects on corneal epithelial cell proliferation,[@bib46]^,^[@bib47] while having stimulatory effects on stromal fibroblast proliferation.[@bib48] Thus, its increased synthesis in the wounded area can lead to delayed re-epithelialization, increased fibroblast proliferation, increased extracellular matrix synthesis, and acceleration of myofibroblast differentiation. Our results showed a significant increase in the synthesis of TGF-β1 after alkali injury ([Fig. 1](#fig1){ref-type="fig"}). Research indicates that functional and structural defects in the epithelial basement membrane generated after corneal injury result in movement of TGF-β1 from the epithelium to the stroma.[@bib49]^,^[@bib50] This causes its receptor activation in these cells,[@bib51] leading to downstream signaling events that result in myofibroblast differentiation of the otherwise relatively quiescent keratocytes,[@bib35]^,^[@bib52] suppression of apoptosis in the myofibroblasts and their precursors,[@bib53] their subsequent accumulation in the stroma, and a consequent corneal opacity. Because TGF-β1 has been shown to be required for corneal healing,[@bib6]^--^[@bib8] preventing the excessive activation of its receptors and not totally blocking its signaling in the corneal stroma upon epithelial injury could be an effective way of preventing fibrosis.

TGF-β1 overexpression induces VEGF and MCP-1 expression at the site of injury, leading to neovascularization and inflammation.[@bib9]^,^[@bib10] Although our work focused only on fibrosis or myofibroblast activation, AICAR has also been shown to suppress inflammation by inhibiting nuclear factor kappa B via AMPK-dependent and independent pathways,[@bib54]^--^[@bib56] as well as the AMPK-dependent activation of the protein deacetylase Sirt[@bib57] in immune cells. Indeed, the systemic administration of AICAR and metformin, another pharmacological AMPK activator, in the treatment of type 2 diabetes mellitus and in wound healing is premised on their anti-inflammatory actions in addition to their major modes of action.[@bib58]^--^[@bib61] Taken together with our results, AICAR may be inhibiting alkali injury-induced cornea inflammation and accelerating corneal wound healing by reducing the production of angiogenic factors and inflammatory cytokines.

TGF-β1 also plays an important role in modulating ECM remodeling after injury by regulating the expression of matrix metalloproteinases (MMPs), which are proteinases involved in the degradation and removal of ECM from the tissues during repair. A dysregulated expression of MMPs, however, also activates TGF-β1 and stimulates myofibroblast differentiation, forming a bidirectional regulatory loop.[@bib62] Because AICAR downregulated TGF-β1 protein synthesis in cornea fibroblasts, its effect on the expression of MMPs is an interesting area of further research.

Our investigations showed that AMPK activation was involved in the antifibrotic effect, as blocking of the AMPK pathway by Compound C attenuated the antifibrotic response. Studies on the effects of AICAR on mTOR signaling also showed that AMPK activation blocked the mTOR pathway. Other studies have found that mTOR signaling plays an important role in the TGF-β1-induced epithelial--mesenchymal transition,[@bib63]^--^[@bib66] which in turn plays a role in the origin of fibroblasts during organ fibrosis in adult tissues.[@bib67] Our results showed that AICAR suppressed the upregulation of ECM proteins by inhibiting TGF-β1-induced mTOR--p70S6K signaling ([Fig. 6](#fig6){ref-type="fig"}). Previous studies have indicated activation of the mTOR pathway in ocular fibrosis,[@bib68]^,^[@bib69] and, not surprisingly, mTOR inhibitors have exhibited an antifibrotic effect in the corneal tissue.[@bib68]^,^[@bib70] Investigations into Smad and mitogen-activated protein kinase signaling, which are also downstream TGF-β1 signaling, showed that AICAR has no effect on these pathways in cornea fibroblasts ([Supplementary Fig. S2](#iovs-61-6-43_s004){ref-type="supplementary-material"}).

In this study, we showed that activation of the mTORC1 pathway was involved in the fibrotic process that occurred subsequent to corneal alkali injury, mediated by TGF-β1. Furthermore, this study demonstrated that fibrosis induced by corneal alkali injury or TGF-β1 fibrosis could be treated by modulating the AMPK pathway, which is the upstream signal of the mTORC1 pathway. Taking into consideration the cytotoxicity of mTOR inhibitors, an AMPK agonist could be used with greater safety. Research also shows that a drug that specifically blocks myofibroblast differentiation from the precursor cells without adversely affecting other corneal cells would be the best way to inhibit fibrosis.[@bib39] There is a great need to identify such drugs. AMPK activation therapies present a promising alternative adjuvant therapy.
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